JPMorgan Chase & Co. Analysts Give MorphoSys (MOR) a €120.00 Price Target
MorphoSys (ETR:MOR) received a €120.00 ($139.53) target price from stock analysts at JPMorgan Chase & Co. in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 22.14% from the company’s previous close.
Other equities research analysts have also issued reports about the stock. Oddo Bhf set a €116.00 ($134.88) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research report on Thursday, November 8th. Independent Research set a €105.00 ($122.09) price objective on shares of MorphoSys and gave the stock a “neutral” rating in a research report on Thursday, September 27th. Goldman Sachs Group set a €86.00 ($100.00) price objective on shares of MorphoSys and gave the stock a “neutral” rating in a research report on Wednesday, September 26th. Berenberg Bank set a €108.00 ($125.58) target price on shares of MorphoSys and gave the company a “neutral” rating in a research note on Friday, September 7th. Finally, Commerzbank set a €107.00 ($124.42) target price on shares of MorphoSys and gave the company a “neutral” rating in a research note on Wednesday, August 22nd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. MorphoSys has an average rating of “Hold” and an average target price of €97.30 ($113.14).
MorphoSys stock opened at €98.25 ($114.24) on Thursday. MorphoSys has a 52 week low of €49.63 ($57.71) and a 52 week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Recommended Story: What Are Treasury Bonds?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.